Medications · Energy & nutritional

Iron (Compounded)

Iron preparations for deficiency repletion.

Start a prescription All medications →
Iron (Compounded) molecular structure (Essential mineral)

Why this needs to be personal

Why Personalized Iron (Compounded)

FDA-approved iron products were dose-calibrated for a generic adult with iron-deficiency anemia and a tolerable GI tract. The label does not account for the things that actually drive iron repletion in a real patient: how deep the deficit is, whether a proton pump inhibitor or tea or calcium is blocking absorption, whether ferrous sulfate triggers nausea and constipation severe enough to stop the regimen, whether the patient is a child who cannot swallow an adult capsule, whether they are pregnant in the second trimester, and whether daily dosing is suppressing absorption through the hepcidin response that alternate-day stable-isotope studies have now documented. None of those individual factors fit the population-average tablet.

Compounding fills that gap inside a narrow lane. A 503A pharmacy can prepare a flavored liquid ferrous salt at a child-appropriate concentration, an alternate-day morning dose split that takes advantage of the hepcidin-window evidence, a capsule strength between commercial breakpoints for a patient titrating up from intolerance, or a preservative-free preparation for a patient with a documented excipient sensitivity. The elemental iron is the same iron the FDA reviewed; the dose, the vehicle, the flavor, and the schedule are written for one chart. RonanRx does not compound parenteral iron into multi-ingredient infusions, that is the lane where commercial iron sucrose, carboxymaltose, and derisomaltose belong.

This is the older arrangement: a prescriber who knows the patient, a pharmacist who prepares the medicine, and a label with one name on it. Modern state inspection and 503A oversight keep that arrangement honest.

In brief

Iron (Compounded) Explained

Iron is the mineral your body uses to make hemoglobin, the protein in red blood cells that carries oxygen. When iron runs low, you can develop iron-deficiency anemia, which causes fatigue, breathlessness on exertion, headache, and reduced exercise capacity 24. Iron deficiency is the most common nutritional deficiency in the world; women of reproductive age, pregnant patients, and people with chronic blood loss or inflammatory disease are most affected 2526.

Iron can be replaced by mouth (cheap, widely available, but slow and often poorly tolerated because of nausea, constipation, and a metallic taste) or by IV infusion (faster, more complete repletion, useful when oral iron does not work or cannot be tolerated). FDA-approved IV options include iron sucrose (Venofer), ferric carboxymaltose (Injectafer), ferric derisomaltose (Monoferric), ferumoxytol (Feraheme), and low-molecular-weight iron dextran (INFeD) 383940. Each has its own dosing schedule, infusion time, and side-effect pattern 41.

At a glance

Quick Facts About Iron (Compounded)

Category
Essential trace mineral, erythropoietic substrate and mitochondrial cofactor
Active ingredient
Elemental iron, supplied as oral ferrous salts (sulfate, fumarate, gluconate, bisglycinate), oral ferric maltol, or as parenteral colloidal iron-carbohydrate complexes (iron sucrose, ferric carboxymaltose, ferric derisomaltose, ferumoxytol, low-molecular-weight iron dextran)
FDA-approved branded forms
Venofer (iron sucrose, 2000), Injectafer (ferric carboxymaltose, 2013), Monoferric (ferric derisomaltose, 2020), Feraheme (ferumoxytol, 2009), INFeD (low-molecular-weight iron dextran, 1991), Triferic (ferric pyrophosphate citrate for HD dialysate, 2015), plus numerous OTC and prescription oral iron preparations
Routes
Oral, intravenous, intramuscular (rarely)
Evidence posture
Iron repletion in iron-deficiency anemia is one of the longest-standing evidence bases in medicine. Randomized trials support IV iron in heart failure with iron deficiency (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN), in non-dialysis and dialysis CKD (DRIVE, FIND-CKD, REPAIR-IDA, PIVOTAL), in inflammatory bowel disease (FERGIcor), in heavy menstrual bleeding, and in pregnancy.
FDA-approval status
Multiple FDA-approved manufactured oral and IV iron products are available. Compounded iron preparations are not FDA-approved.
Compounded under
503A, patient-specific prescription only. Compounded role is narrow: custom oral concentrations and flavors for pediatric or dysphagic patients, alternate-day liquid pediatric formulations, IM iron at custom doses where commercial product is unsuitable. IV iron is typically dispensed as the manufactured product.
Important compounding caution
Iron salts are physically and chemically incompatible with many infusion components. Adding parenteral iron to compounded amino-acid, B-vitamin, or 'Myers cocktail'-type mixes is generally discouraged because of precipitation, oxidative interactions with ascorbate, and loss of dose accuracy. Each parenteral iron product has a manufacturer-specified diluent and infusion protocol that should be followed.

Prescription review

Patient-Specific Prescription Only

Iron (Compounded) on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.

  • Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
  • Named-patient label. The bottle carries your name. The batch records carry your prescription.
  • Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
  • Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
  • Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
For prescribing doctors Offer this medication → For patients Find a partner clinic →

Real medicine, not gray market

How This Differs from a Research-Use-Only Website

A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.

A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.

What it is

What is Iron (Compounded)?

Iron is a transition metal and essential trace element. Roughly 70% of total body iron is in hemoglobin within circulating erythrocytes, 10, 15% in muscle myoglobin, and the remainder distributed across heme-containing and non-heme iron-sulfur-cluster proteins (cytochromes, ribonucleotide reductase, mitochondrial aconitase, ferritin storage). The adult human contains 3, 4 g of iron, with daily losses of approximately 1 mg in men and non-menstruating women, and 1.5, 3 mg per day on average in menstruating women across the cycle 38. Iron-deficiency anemia develops when intake or absorption fail to keep up with losses over weeks to months 24.

Pharmaceutical iron is supplied either as oral salts (predominantly ferrous sulfate, fumarate, gluconate, or bisglycinate; or as the newer oral ferric maltol) or as parenteral colloidal complexes in which an iron(III) oxyhydroxide core is shielded by a carbohydrate shell (sucrose, carboxymaltose, isomaltoside/derisomaltose, polyglucose-sorbitol-carboxymethyl-ether, or dextran) 38 42. The carbohydrate shell determines stability, infusion-rate ceiling, single-dose limit, and the kinetics of iron release to transferrin. These differences underlie meaningful clinical distinctions in administration time, total-dose-infusion capability, and adverse-event profile 3435.

FDA-approved parenteral iron products in the United States are iron sucrose (Venofer, approved 2000), sodium ferric gluconate complex (Ferrlecit, approved 1999), low- and high-molecular-weight iron dextrans (INFeD; the older Dexferrum was withdrawn 2014), ferumoxytol (Feraheme, approved 2009), ferric carboxymaltose (Injectafer, approved 2013), ferric derisomaltose (Monoferric, approved 2020, the same molecule previously marketed in Europe as iron isomaltoside 1000/Monofer), and ferric pyrophosphate citrate for hemodialysate addition (Triferic, approved 2015) 394041.

How it works

How Iron (Compounded) Works

Class
Essential mineral
First studied
Centuries of clinical use
Common forms
Compounded oral capsule
Compounding category
503A, patient-specific prescription

Iron is required for oxygen transport (hemoglobin, myoglobin), electron transport (cytochromes), DNA synthesis (ribonucleotide reductase), and dozens of mitochondrial and cytosolic enzymes. Without adequate iron, erythropoiesis is rate-limited at the heme-synthesis step, red cells produced are microcytic and hypochromic, oxygen-carrying capacity falls, and tissue oxygen delivery is compromised 35.

Systemic iron is regulated almost entirely at the level of absorption and macrophage iron recycling, mediated by the hepatic hormone hepcidin acting on the cellular iron exporter ferroportin. When body iron stores are adequate, hepcidin rises and ferroportin is internalized and degraded, blocking duodenal absorption and macrophage iron release. When iron stores are low or erythropoietic drive is high, hepcidin falls and absorption rises 35.

Pharmacologically, oral iron supplies elemental iron to duodenal enterocytes for absorption via DMT1 after reduction at the apical brush border. Intravenous iron bypasses the gut entirely: the colloidal iron-carbohydrate complex is taken up by macrophages of the reticuloendothelial system (predominantly liver and spleen), and iron is gradually released to transferrin for delivery to the bone marrow over hours to days. Single large doses of stable modern IV iron formulations therefore physiologically simulate weeks of effective oral absorption 34 35.

Research history

Iron (Compounded) Research History

Iron has been used therapeutically since antiquity, and ferrous sulfate as the modern oral iron salt has been in continuous use since the nineteenth century. The first injectable iron, iron-saccharated colloid, was introduced in the 1930s, followed in the 1950s by high-molecular-weight iron dextran (Imferon), which became dominant for parenteral iron until the late 1990s but accumulated a substantial signal for anaphylactoid reactions that limited its uptake 34. The Global Burden of Disease analyses 27 confirmed iron-deficiency anemia as the leading cause of years lived with disability among nutritional conditions worldwide.

Iron sucrose (Venofer) entered the US market in 2000 and was rapidly adopted in the dialysis-CKD setting, where the DRIVE trial 7 demonstrated that IV iron in hyperferritinemic, low-TSAT hemodialysis patients on erythropoietin produced meaningful hemoglobin response, challenging the prior ferritin-based ceiling on IV iron use. PIVOTAL 10 subsequently showed that a proactive, high-dose IV iron strategy in incident hemodialysis was non-inferior to a reactive low-dose strategy on cardiovascular events and reduced erythropoietin requirements. Non-dialysis CKD evidence came from FIND-CKD 8 (FCM superior to oral iron) and REPAIR-IDA 9 (FCM versus iron sucrose).

Ferric carboxymaltose was FDA-approved as Injectafer in 2013, ferumoxytol as Feraheme in 2009 (originally also developed as an MR contrast agent), and ferric derisomaltose as Monoferric in January 2020 in the US. These modern non-dextran colloidal preparations support single-dose infusion of 500, 1000 mg or, for FDI, a single 20-mg/kg infusion to complete repletion 121335.

The heart-failure indication for IV iron originated with FERRIC-HF 5, in which iron sucrose improved exercise tolerance in iron-deficient HFrEF. FAIR-HF 1 established symptom and quality-of-life benefit with ferric carboxymaltose regardless of anemia status. CONFIRM-HF 2 extended benefit to 52 weeks, AFFIRM-AHF 3 addressed the post-acute setting at hospital discharge, and IRONMAN 4 tested ferric derisomaltose in UK chronic HF. IRONOUT-HF 6 separately showed that oral iron polysaccharide was not adequate in HFrEF, supporting the IV route specifically. Inflammatory bowel disease evidence came from FERGIcor 11. Heavy-menstrual-bleeding and pregnancy evidence developed through UK and international guideline syntheses 182023.

Timeline

Iron (Compounded) Timeline

  1. 1832 Pierre Blaud popularizes the 'Blaud pill' of ferrous sulfate and potassium carbonate as a treatment for chlorosis, the first systematic oral iron pharmacotherapy
  2. 1950s High-molecular-weight iron dextran (Imferon) introduced as the first widely used parenteral iron, eventually withdrawn for hypersensitivity-reaction burden 34
  3. 1991 FDA approves low-molecular-weight iron dextran (INFeD) for treatment of iron-deficiency anemia in patients unable to take oral iron 42
  4. 2000 FDA approves iron sucrose (Venofer) for iron-deficiency anemia in CKD 38
  5. 2007 DRIVE trial (Coyne et al., J Am Soc Nephrol) demonstrates that IV ferric gluconate produces hemoglobin response in hyperferritinemic, low-TSAT hemodialysis patients on erythropoietin 7
  6. 2008 FERRIC-HF (Okonko et al., JACC), IV iron sucrose improves exercise tolerance in iron-deficient symptomatic HFrEF 5
  7. 2009 FDA approves ferumoxytol (Feraheme) for iron-deficiency anemia in CKD; FAIR-HF (Anker et al., NEJM) demonstrates symptom and quality-of-life benefit of ferric carboxymaltose in chronic HFrEF with iron deficiency, regardless of anemia status 411
  8. 2011 FERGIcor (Evstatiev et al., Gastroenterology), ferric carboxymaltose superior to iron sucrose for IDA in inflammatory bowel disease 11
  9. 2013 FDA approves ferric carboxymaltose as Injectafer for iron-deficiency anemia in adults intolerant of, or with unsatisfactory response to, oral iron 39
  10. 2014 Kassebaum et al 14. (Blood) Global Burden of Disease analysis, iron-deficiency anemia is the leading cause of YLD among nutritional conditions; FIND-CKD (Macdougall et al., NDT), high-ferritin-target IV FCM superior to oral iron in non-dialysis CKD; REPAIR-IDA (Onken et al., NDT), FCM vs iron sucrose in IDA with impaired renal function; Hetzel et al 2789. (Am J Hematol), ferumoxytol non-inferior to iron sucrose
  11. 2015 CONFIRM-HF (Ponikowski et al., Eur Heart J), sustained benefit of IV ferric carboxymaltose over 52 weeks in chronic HFrEF; Camaschella IDA review in NEJM; Lopez et al 22425. IDA seminar in Lancet 2016; Moretti et al. (Blood) describe oral iron-induced hepcidin rise that blunts absorption of subsequent doses; Tolkien et al 30. (PLoS One) systematic review confirms substantial GI AE rate with ferrous sulfate; Avni et al 3231. (Mayo Clin Proc) meta-analysis of IV iron safety
  12. 2017 Stoffel et al. (Lancet Haematol), alternate-day single-morning oral iron absorbs more per dose than daily or twice-daily dosing; Munoz et al 28226. international consensus on perioperative anaemia management; IRONOUT-HF (Lewis et al., JAMA), oral iron does not improve peak VO2 in HFrEF
  13. 2018 Adkinson et al. (Am J Hematol), head-to-head comparative safety of ferumoxytol vs FCM in IDA; IRLSSG/Allen et al 15. (Sleep Med) consensus on iron treatment of restless legs syndrome including IV iron when ferritin <75 ng/mL; Daru et al 1923. (Lancet Glob Health), severe maternal anaemia and mortality
  14. 2019 PIVOTAL trial (Macdougall et al., NEJM), proactive high-dose IV iron non-inferior to reactive low-dose in incident hemodialysis on cardiovascular endpoint; FERWON-IDA (Auerbach et al., Am J Hematol), ferric derisomaltose vs iron sucrose for IDA 1013
  15. 2020 FDA approves ferric derisomaltose (Monoferric) for non-CKD IDA in adults intolerant of oral iron; AFFIRM-AHF (Ponikowski et al., Lancet), IV ferric carboxymaltose at discharge after acute heart failure; UK BSH iron-in-pregnancy guideline (Pavord et al., BJH); Wolf et al 40318162137. (JAMA) randomized comparison of hypophosphatemia after FCM vs FDI; PREVENTT (Richards et al., Lancet), preoperative IV iron in abdominal surgery; Means iron-deficiency review (Nutrients)
  16. 2021 Pasricha et al. (Lancet) iron-deficiency seminar; FERWON-NEPHRO (Bhandari et al., NDT), FDI vs iron sucrose in non-dialysis CKD; Mansour et al 261220. clinical-guideline review of HMB management
  17. 2022 IRONMAN (Kalra et al., Lancet), ferric derisomaltose in UK chronic heart failure with iron deficiency; Schaefer et al 417. (JCEM) on persistent and severe hypophosphatemia after FCM
  18. 2024 Auerbach et al 35. (Am J Hematol) expert consensus on intravenous iron uses, formulations, administration, and reaction management
  19. 2025 Auerbach et al 36. (JAMA) state-of-the-art review of iron deficiency in adults

Natural role

Biological Role of Iron (Compounded)

Iron is essential to oxygen transport, mitochondrial respiration, and DNA synthesis. It is the catalytic metal at the active site of every cytochrome in the electron transport chain, of ribonucleotide reductase that supplies deoxyribonucleotides for DNA replication, and of dozens of dehydrogenases, hydroxylases, and oxygenases including prolyl hydroxylase (the oxygen sensor that controls HIF-α) and aromatic amino-acid hydroxylases that generate dopamine and serotonin. Brain iron deficiency in particular impairs dopaminergic signaling, which underlies the well-documented restless-legs-syndrome phenotype in patients with low brain iron stores even at normal hemoglobin 19.

Body iron is partitioned: hemoglobin in circulating erythrocytes (~2.5 g in an adult), storage as ferritin and hemosiderin in liver, spleen, and bone marrow macrophages (~1 g), myoglobin in muscle (~0.3 g), and the remainder in enzymes. Iron is conserved aggressively, there is no regulated excretory pathway, and net losses are limited to desquamated cells, sweat, urinary tubular cells, and blood loss. This evolutionary economy is also why iron overload, when it occurs (transfusion-dependent, HFE hemochromatosis, repeated parenteral iron in low-iron-loss patients), produces hepatic, cardiac, and endocrine end-organ damage.

Clinical contexts studied

Clinical Contexts for Iron (Compounded)

Iron-deficiency anemia in adults intolerant of, or with unsatisfactory response to, oral iron, non-dialysis CKD or non-CKD fda approved

FDA-approved indications across multiple manufactured IV iron products.

Manufactured IV iron products are labeled for IDA in adults who cannot tolerate or do not respond to oral iron 4142. FCM (Injectafer) and FDI (Monoferric) are labeled in adults without restriction to CKD; iron sucrose (Venofer) is labeled in CKD (HD, PD, and non-dialysis); ferumoxytol (Feraheme) is labeled for IDA in adults intolerant of or with unsatisfactory response to oral iron and in CKD 383940. Phase 3 evidence supporting these labels includes FIND-CKD 8, REPAIR-IDA 9, FERWON-IDA 13, FERWON-NEPHRO 12, the Hetzel ferumoxytol vs iron sucrose trial 14, and the Adkinson FCM vs ferumoxytol head-to-head 15.

Branded product: Venofer (iron sucrose), Injectafer (ferric carboxymaltose), Monoferric (ferric derisomaltose), Feraheme (ferumoxytol), INFeD (iron dextran)

Iron-deficiency anemia in adults with chronic kidney disease on hemodialysis fda approved

FDA-approved indication for iron sucrose (Venofer) and ferric pyrophosphate citrate (Triferic); broad use evidence base.

Iron sucrose is labeled for IDA in adults with CKD including those on hemodialysis 38. Evidence supporting IV iron in dialysis CKD includes DRIVE 7 (response in hyperferritinemic, low-TSAT HD patients) and PIVOTAL 10 (proactive high-dose IV iron non-inferior to reactive low-dose on cardiovascular endpoint with reduced erythropoietin requirement). Triferic is added to the hemodialysate to replace ongoing iron losses on dialysis.

Branded product: Venofer (iron sucrose); Triferic (ferric pyrophosphate citrate dialysate)

Symptomatic chronic heart failure with reduced ejection fraction and iron deficiency well studied

Studied in dedicated randomized phase 3 trials; ESC heart failure guidelines recommend IV iron in this population. Not a separately labeled US indication.

FAIR-HF 1 randomized 459 adults with NYHA II, III HFrEF and iron deficiency (ferritin <100 ng/mL, or 100, 299 with TSAT <20%) to IV FCM or saline placebo; the primary patient-global-assessment and 6-minute-walk endpoints favored FCM. CONFIRM-HF 2 confirmed sustained benefit over 52 weeks. AFFIRM-AHF 3 tested IV FCM at discharge after acute HF, the primary composite (recurrent HF hospitalization + CV death) showed a numerical reduction that did not reach statistical significance under the prespecified COVID-19-adjusted analysis. IRONMAN 4 tested ferric derisomaltose in UK chronic HF and reported a reduction in HF hospitalization and CV death in the COVID-19-adjusted analysis. FERRIC-HF 5 with iron sucrose preceded these and showed exercise-tolerance benefit. Oral iron polysaccharide was negative on peak VO2 in IRONOUT-HF 6, supporting the IV route specifically.

Iron-deficiency anemia in inflammatory bowel disease well studied

Studied in FERGIcor and supported by IBD society guidelines.

FERGIcor 11 randomized 485 adults with IBD and IDA to ferric carboxymaltose or iron sucrose. FCM was superior to iron sucrose on the primary hemoglobin response endpoint at 12 weeks, with fewer infusions required. Oral iron in active IBD is often poorly tolerated because of mucosal exposure and can exacerbate inflammation in some patients; IV iron is the preferred route in moderate-to-severe active disease.

Iron deficiency in pregnancy well studied

Oral iron first-line per UK BSH guidelines; IV iron from second trimester onward when oral iron fails, is not tolerated, or rapid repletion is required.

UK BSH 2019 guidelines on iron in pregnancy 18 frame oral iron as first-line for IDA and prophylaxis where indicated, with IV iron (FCM, FDI, or iron sucrose) reserved for second-trimester-onward use in oral-iron failure, intolerance, severe anemia near term, or specific obstetric scenarios. The maternal-mortality signal in severe antenatal anemia 23 underlies the urgency to correct anemia before delivery.

Iron-deficiency anemia secondary to heavy menstrual bleeding well studied

Routine indication; IV iron is recommended where oral iron fails or rapid repletion is required.

Clinical-guideline review 20 frames IV iron (FCM, FDI, or iron sucrose) as appropriate in HMB-related IDA where oral iron has failed, has produced unacceptable GI side effects, or is insufficient to keep up with menstrual losses. Treatment of the underlying HMB (hormonal, surgical) is the separate question.

Restless legs syndrome / Willis, Ekbom disease in adults with low iron stores well studied

IRLSSG consensus recommends IV iron when ferritin <75 ng/mL and oral iron has failed.

Allen et al. IRLSSG consensus 19 recommends a trial of oral iron when peripheral ferritin is below 75 ng/mL and considers IV iron (FCM, ferumoxytol, or iron sucrose; iron dextrans are not generally recommended) when oral iron has failed, is not tolerated, or rapid response is desired. Brain iron, not peripheral hemoglobin, is the relevant pool; many RLS patients are not anemic.

Pre-operative anemia before major elective surgery well studied

International consensus supports IV iron repletion; PREVENTT trial findings nuanced.

International consensus 22 recommends correction of pre-operative anemia, including IV iron where indicated, to reduce transfusion need and improve postoperative outcomes. PREVENTT 21 randomized 487 anaemic adults undergoing major abdominal surgery to IV FCM or placebo 10, 42 days pre-op; the co-primary endpoints of death/transfusion and number of transfusions were not met, but pre-specified secondary analyses suggested fewer readmissions and improved 8-week post-discharge hemoglobin.

Off-label use

Off-Label Uses of Iron (Compounded)

Iron deficiency without anemia in fatigue or athletic performance emerging

Off-label; mixed evidence. Oral iron may benefit fatigue in non-anemic iron-deficient women in some trials but the effect size is modest.

Some randomized data suggest fatigue improvement with iron repletion in non-anemic women with low ferritin, but trial quality and effect sizes vary. The Auerbach 2024 expert consensus and the 2025 JAMA review recommend evaluating ferritin and considering iron repletion in non-anemic iron-deficient adults with fatigue, while cautioning against routine IV iron for fatigue alone without documented deficiency 3536.

FDA-approved use

FDA-Approved Uses of Iron (Compounded)

BrandIndicationYearRoute
Venofer (iron sucrose) Iron-deficiency anemia in adults and pediatric patients ≥2 years with chronic kidney disease (HD, PD, or non-dialysis) 2000 Intravenous
Injectafer (ferric carboxymaltose) Iron-deficiency anemia in adults intolerant of or with unsatisfactory response to oral iron; in adults with non-dialysis-dependent CKD; iron deficiency in adults with NYHA II/III heart failure (added) 2013 Intravenous
Monoferric (ferric derisomaltose) Iron-deficiency anemia in adults intolerant of oral iron or with non-hemodialysis-dependent CKD 2020 Intravenous
Feraheme (ferumoxytol) Iron-deficiency anemia in adults intolerant of or with unsatisfactory response to oral iron, including those with CKD 2009 Intravenous
INFeD (low-molecular-weight iron dextran) Iron-deficiency anemia in adults in whom oral iron is unsatisfactory or impossible 1991 Intravenous or intramuscular

Multiple manufactured iron products are FDA-approved. Oral iron is available as numerous OTC and prescription ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrous bisglycinate, polysaccharide-iron complex, and ferric maltol preparations. Parenteral iron is available as iron sucrose (Venofer), ferric carboxymaltose (Injectafer), ferric derisomaltose (Monoferric), ferumoxytol (Feraheme), low-molecular-weight iron dextran (INFeD), and ferric pyrophosphate citrate for hemodialysate addition (Triferic) 384041.

Each parenteral iron product carries product-specific labeling on hypersensitivity warnings, infusion duration, single-dose limits, and post-infusion monitoring 38. Injectafer and Feraheme labels include warnings regarding serious hypersensitivity reactions; Injectafer carries a specific warning on symptomatic hypophosphatemia 39. INFeD historically carried a Boxed Warning for anaphylactic-type reactions including a test-dose requirement 42.

Compounded use

Compounded Iron (Compounded) (503A)

The 503A compounded role for iron is narrow. The IV iron products listed above are manufactured, FDA-approved, and widely available; compounding parenteral iron from bulk in a 503A pharmacy is rarely clinically necessary and is not a routine RonanRx service. Adding parenteral iron to multi-ingredient infusions (compounded amino-acid mixes, B-complex bags, 'Myers cocktail'-style preparations) is generally discouraged because iron is physically and chemically incompatible with many of those components: iron precipitates with phosphate; oxidizes ascorbate; reacts with thiols (glutathione, N-acetylcysteine); and is destabilized at pH extremes and with calcium gluconate. Each manufactured IV iron product specifies a permitted diluent (normal saline, often only in a defined volume) and an infusion rate ceiling; deviations from labeled administration are a documented source of free-iron reactions 393835.

Legitimate 503A iron compounding scenarios include: (1) custom-strength oral liquid iron for pediatric patients or for adults with dysphagia, especially when a clinically appropriate alternate-day dosing schedule 28 is desired and no commercial product matches the prescriber's mg-per-mL and flavor specifications; (2) excipient-free or specific-excipient oral preparations for patients with documented sensitivity to a component of commercial iron tablets or liquids; (3) IM iron dextran in non-standard volumes for patients in whom IV access is impossible and IM administration is appropriate, when no manufactured product matches the prescribed regimen. In all cases the compound is dispensed only on a patient-specific prescription with a documented clinical reason that the manufactured product cannot meet 4344.

RonanRx does not compound parenteral iron into multi-ingredient infusion bags. RonanRx does not compound or dispense 'iron infusions' as a routine wellness service. Manufactured Venofer, Injectafer, Monoferric, and Feraheme are the standard of care for IV iron; the compounded oral and (rarely) IM iron preparations described above are the only iron preparations RonanRx produces and only on documented patient-specific need.

Formulations and routes

Iron (Compounded) Formulations and Routes

FormConcentrationDescription
Compounded oral liquid (503A) Custom mg elemental iron per mL, typical pediatric strengths include ferrous sulfate 75 mg/mL (15 mg elemental iron/mL) or lower, flavored to improve adherence Patient-specific oral liquid prepared under USP <795>. Used when manufactured pediatric liquid iron is not available in the prescribed strength, when a specific flavoring or excipient profile is required, or to support alternate-day single-morning dosing in pediatric or dysphagic adults.4528
Compounded oral capsule (503A) Custom elemental iron strength, typically 25, 65 mg per capsule Patient-specific oral solid prepared under USP <795> with documented potency. Used when a manufactured product at the prescribed strength is unavailable or when a specific excipient profile is required.45
Manufactured oral preparations (reference products) Ferrous sulfate 325 mg (65 mg elemental), ferrous fumarate 324 mg (106 mg elemental), ferrous gluconate 324 mg (38 mg elemental), polysaccharide-iron 150 mg elemental, ferric maltol 30 mg elemental Standard OTC and prescription oral iron preparations. Ferrous salts are absorbed similarly per elemental iron content; differences in GI tolerability are modest and dose-dependent [tolkien2015].32
Manufactured IV iron sucrose (Venofer; reference product) 20 mg elemental iron per mL; 5 mL or 10 mL single-dose vials Slow IV push of 100 mg over 2, 5 min or infusion of 200, 300 mg over ≥15 min, typically 5, 10 doses per repletion course. CKD-labeled.38
Manufactured IV ferric carboxymaltose (Injectafer; reference product) 50 mg elemental iron per mL; 15 mL single-dose vials Two 750 mg doses at least 7 days apart (cumulative 1500 mg) or 15 mg/kg up to 750 mg infused over ≥15 min. Single-dose label option in non-US markets allows up to 1000 mg in one infusion.39
Manufactured IV ferric derisomaltose (Monoferric; reference product) 100 mg elemental iron per mL; 1 mL or 10 mL single-dose vials 1000 mg over ≥20 min as a single dose for patients with weight ≥50 kg; 20 mg/kg up to a maximum 1000 mg total dose otherwise. Designed for total-dose infusion in one or two visits.40
Manufactured IV ferumoxytol (Feraheme; reference product) 30 mg elemental iron per mL; 17 mL single-dose vials (510 mg per vial) Two 510 mg doses 3, 8 days apart (cumulative 1020 mg) infused over ≥15 min. Originally also developed as an MR contrast agent.41
Manufactured IV/IM low-molecular-weight iron dextran (INFeD; reference product) 50 mg elemental iron per mL Total-dose infusion possible but requires test dose and longer infusion than non-dextran products. Largely supplanted in clinical practice by FCM, FDI, and ferumoxytol where available.42

Routes used in published literature: oral, intravenous, intramuscular.

Dosing

Iron (Compounded) Dosing

RoutePopulationRangeDurationStudy type
Oral Adults with iron-deficiency anemia (non-pregnant) 40, 100 mg elemental iron per dose, given as a single morning dose every other day or daily for a planned course of 8, 12 weeks beyond hemoglobin normalization to replete stores 8, 12 weeks beyond Hb normalization, then reassess ferritin Mechanistic stable-isotope absorption studies and clinical-guideline consensus30282935
Oral Adults with iron deficiency in pregnancy Per UK BSH 2019: 40, 80 mg elemental iron daily for prophylaxis where indicated; 100, 200 mg elemental iron daily for treatment of established IDA Continued through pregnancy and at least 3 months postpartum UK BSH 2019 guideline18
Intravenous Adults with IDA (iron sucrose / Venofer) 100, 200 mg per dose over 15, 30 min; typical cumulative repletion 1000 mg over 5, 10 doses Course over 2, 3 weeks FDA-approved labeled regimen38
Intravenous Adults with IDA (ferric carboxymaltose / Injectafer) Two doses of 750 mg ≥7 days apart (cumulative 1500 mg) infused over ≥15 min; or 15 mg/kg up to 750 mg single dose Single or two-dose course FDA-approved labeled regimen39
Intravenous Adults with IDA (ferric derisomaltose / Monoferric) 1000 mg single infusion over ≥20 min (weight ≥50 kg); 20 mg/kg up to a maximum 1000 mg single infusion otherwise; repeat as required to a calculated total iron deficit Single-dose total-dose-infusion regimen FDA-approved labeled regimen40
Intravenous Adults with IDA (ferumoxytol / Feraheme) Two 510 mg doses 3, 8 days apart (cumulative 1020 mg) infused over ≥15 min Two-dose course FDA-approved labeled regimen41
Intravenous Adults with HFrEF and iron deficiency (off-label US, guideline-recommended internationally) Ferric carboxymaltose dosed by weight and Hb per FAIR-HF / CONFIRM-HF schedule (typical cumulative 500, 2000 mg over multiple visits); IRONMAN used ferric derisomaltose dosed by weight every 4 months as required Indefinite while iron-deficient and clinically beneficial Phase 3 RCT regimens1234
Intramuscular Adults unable to take oral or IV iron (rare) Iron dextran 100 mg per injection at separate gluteal sites with Z-track technique; total dose calculated by weight and Hb deficit Multi-injection course FDA-approved INFeD label; rarely used in modern practice42

Oral iron is first-line for most non-pregnant adults with uncomplicated IDA. Single-morning alternate-day dosing of 40, 100 mg elemental iron is now supported by direct stable-isotope absorption data 302829 and produces less GI symptom burden than daily or twice-daily dosing 32. A typical adult repletion course is 8, 12 weeks beyond hemoglobin normalization to refill ferritin stores. Patients should be counseled to take oral iron away from calcium, proton pump inhibitors, and tea, all of which materially reduce non-heme iron absorption 33.

Intravenous iron should be used when oral iron has failed, is not tolerated, is contraindicated, or when rapid repletion is needed. Choice of IV iron product is driven by access, single-dose-infusion capability, and patient-specific safety considerations. FCM is widely available and convenient but carries the highest risk of clinically meaningful hypophosphatemia, particularly in patients with normal kidney function and ongoing causes of urinary iron-FGF23-axis stimulation 1617. FDI is a total-dose-infusion option with markedly less hypophosphatemia. Ferumoxytol and iron sucrose are appropriate alternatives. Modern non-dextran preparations have a much lower hypersensitivity-reaction profile than the historic iron dextrans 3435.

Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.

Safety

Iron (Compounded) Safety

Safety overview

Oral iron safety is dominated by gastrointestinal adverse events. The Tolkien et al. systematic review and meta-analysis 32 reported nausea, abdominal pain, constipation, diarrhea, and dark stool occurring substantially more often with ferrous sulfate than placebo, with an overall GI AE odds ratio of approximately 2.3. AE rate scales with dose; alternate-day single-morning dosing reduces both daily exposure and aggregate GI symptom burden 28. Oral iron should be taken away from PPIs, calcium, and tea to preserve absorption 33. Acute oral iron overdose in children is a clinically important poisoning syndrome and is the basis for the FDA-mandated child-resistant packaging on oral iron products containing ≥30 mg elemental iron per dosage unit.

Intravenous iron safety is dominated by infusion reactions and, with FCM specifically, hypophosphatemia 4. Pooled safety analyses of modern non-dextran IV iron preparations 313435 report a serious-hypersensitivity-reaction rate of approximately 0.04, 0.1 per 100 administrations, much lower than the historic 0.6, 0.7 per 100 reported with high-molecular-weight iron dextran. The Adkinson head-to-head trial 15 reported broadly comparable composite hypersensitivity rates between FCM and ferumoxytol with each product showing a distinct subtype distribution. Mild 'Fishbane reaction' (transient flushing, chest tightness, back/joint pain without true anaphylaxis) is rate-related and resolves with infusion-rate reduction.

FCM-induced hypophosphatemia is now a well-characterized adverse event. Wolf et al. 16 randomized adults with IDA to FCM or FDI; incident hypophosphatemia (phosphate <2.0 mg/dL) occurred in 75% on FCM vs 8% on FDI by day 14, and severe hypophosphatemia (<1.3 mg/dL) in 12% on FCM vs <1% on FDI. Schaefer et al. 17 characterized persistent (>2-week) and severe hypophosphatemia following FCM, with risk factors including lower baseline phosphate, normal kidney function, and higher cumulative FCM dose. Clinical sequelae include weakness, bone pain, and, with repeated dosing, osteomalacia and stress fractures; routine baseline phosphate measurement and phosphate monitoring after FCM, and preferential use of FDI in patients requiring repeated IV iron, are now recommended 35 3. Iron sucrose, ferumoxytol, and iron dextran do not produce clinically meaningful hypophosphatemia.

Cardiovascular safety of IV iron in heart failure with iron deficiency is supported by FAIR-HF, CONFIRM-HF, AFFIRM-AHF, and IRONMAN; in maintenance hemodialysis the PIVOTAL trial 10 reported non-inferiority of a proactive high-dose IV iron strategy versus a reactive low-dose strategy on the cardiovascular composite 12. Pre-specified meta-analyses of IV iron safety 31 did not find an excess of serious infections with IV iron. Iron-overload safety (transferrin saturation persistently >50%, ferritin >500, 800 ng/mL in non-inflammatory states) is the relevant concern with repeated dosing in low-iron-loss populations and is monitored by serial ferritin and TSAT 35.

Contraindications

Iron is contraindicated in: known hypersensitivity to the specific iron preparation or to any of its excipients; anemia not caused by iron deficiency (the indication is iron deficiency, not anemia of other cause); and iron overload syndromes including HFE hemochromatosis with elevated ferritin, transfusional iron overload, and other primary iron-loading disorders. Parenteral iron is additionally contraindicated in patients with a history of serious hypersensitivity reaction to any IV iron product 38.

Caution is warranted in active systemic infection, where IV iron is typically deferred until the infection is controlled because of theoretical concerns about iron and bacterial virulence (the supporting evidence on real-world infection risk is mixed and pooled safety analyses have not consistently shown a clear excess). Caution is also warranted in patients with multiple drug allergies and asthma due to higher reported rates of mild infusion reactions 3539 384041.

Drug interactions

Oral iron absorption is reduced by concomitant proton pump inhibitors, H2 blockers, calcium-containing supplements and dairy, antacids, levothyroxine, fluoroquinolone and tetracycline antibiotics, bisphosphonates, levodopa, mycophenolate, and tea polyphenols. Where coadministration is necessary, oral iron should be spaced by at least 2 hours from the interacting agent 33. Ascorbic acid 200 mg coadministered with oral iron increases fractional absorption modestly; the clinical importance is debated and the addition is not universally required.

Intravenous iron has limited pharmacokinetic drug-drug interactions beyond temporary interference with serum iron and transferrin saturation measurements (which should be interpreted with caution within 1, 2 weeks of an IV iron dose). Concomitant erythropoiesis-stimulating agents are commonly co-administered in CKD and are not contraindicated; in fact, IV iron substantially reduces the ESA dose required in many patients 710.

Adverse events

Most common adverse events with oral iron are gastrointestinal: nausea, abdominal pain, constipation, diarrhea, and dark stool. Tolkien et al. 32 reported pooled OR ~2.3 for any GI AE with ferrous sulfate vs placebo and ~1.5 for any GI AE with ferrous sulfate vs other oral iron preparations; the absolute event rates remain substantial across all oral iron salts.

Most common adverse events with IV iron are mild infusion-site and Fishbane-type reactions (flushing, chest tightness, back/joint pain, usually rate-related and self-limited), transient muscle aches, and transient post-infusion headache. Serious hypersensitivity reactions are rare with modern non-dextran preparations (~0.04, 0.1 per 100 administrations) 3135. Hypophosphatemia is frequent with FCM (75% by day 14 in randomized data) and infrequent with FDI, iron sucrose, ferumoxytol, and iron dextran 1617. The Adkinson head-to-head 15 reported broadly comparable composite hypersensitivity rates between FCM and ferumoxytol. Hetzel et al. 14 reported non-inferiority of ferumoxytol vs iron sucrose. Iron-overload risk with repeated IV iron is monitored by ferritin and TSAT.

Monitoring

Monitoring Iron (Compounded) Therapy

Baseline assessment for any patient being started on iron therapy: complete blood count with indices, ferritin, transferrin saturation (iron and TIBC), and reticulocyte count if anemia is present; identification of the underlying cause of deficiency (menstrual loss, GI loss, malabsorption, dietary inadequacy, increased demand) is mandatory before committing to a repletion course 35.

On-therapy monitoring: hemoglobin and ferritin at 4, 8 weeks of oral iron to confirm response (expected Hb rise ≥1 g/dL by 4 weeks); ferritin and TSAT at completion of an IV iron course to confirm repletion and at intervals during ongoing dosing to avoid iron overload (target ferritin generally <500 ng/mL in non-CKD, with TSAT <50%). After FCM specifically, baseline and post-infusion serum phosphate are recommended given the documented hypophosphatemia signal 1617. Patients on chronic IV iron should be re-evaluated periodically to ensure continued indication 35.

Special populations

Iron (Compounded) in Special Populations

Pregnancy

Iron deficiency is common in pregnancy and severe antenatal anemia is associated with increased maternal mortality risk 23. UK BSH 2019 guidelines 18 frame oral iron as first-line for both prophylaxis (where indicated) and treatment of established iron deficiency in pregnancy. IV iron (FCM, FDI, or iron sucrose) is recommended from the second trimester onward where oral iron has failed, is not tolerated, where severe IDA is diagnosed close to term, or where rapid repletion is required. First-trimester IV iron is generally avoided in the absence of compelling clinical need.

Lactation

Oral and IV iron are generally considered compatible with breastfeeding. Iron crosses into breast milk in tightly regulated, small amounts; supplementation of the iron-replete mother does not appreciably alter milk iron content, and supplementation of the iron-deficient mother is appropriate when clinically indicated 18.

Pediatric

Iron deficiency is the most common cause of anemia in children worldwide 27. First-line repletion is oral iron at 3, 6 mg/kg/day elemental iron for established IDA, typically given once daily or, increasingly, as a single morning dose every other day to optimize absorption and reduce GI side effects in older children 28. Custom compounded oral liquid iron at a non-commercial strength or alternate-day specification is a legitimate 503A scenario when no manufactured pediatric product matches the prescribed regimen. IV iron in children is reserved for refractory cases (severe IBD, oncology, chronic dialysis) and is given as iron sucrose, FCM, or, in adolescents, FDI per product-specific pediatric labeling and institutional protocol 38.

Geriatric

Iron deficiency in older adults is frequently a marker of occult GI blood loss and warrants endoscopic evaluation in most cases before committing to a repletion-only course. Oral iron is often poorly tolerated in older adults at standard doses; alternate-day dosing reduces the GI burden 28. IV iron is appropriate when oral iron is not tolerated or has failed and is well tolerated in older adults at standard manufactured-product doses 35.

Renal impairment

Iron sucrose (Venofer) is the long-standing FDA-approved option for CKD-IDA and is labeled in HD, PD, and non-dialysis CKD 38. FCM (Injectafer) is labeled in non-dialysis-dependent CKD. FDI (Monoferric) is labeled in non-hemodialysis-dependent CKD. PIVOTAL 10 supported proactive high-dose IV iron in incident hemodialysis on a cardiovascular non-inferiority endpoint with reduced ESA requirement. FIND-CKD 8 and REPAIR-IDA 9 support IV iron in non-dialysis CKD. FERWON-NEPHRO 12 compared FDI with iron sucrose in non-dialysis CKD and reported non-inferiority on hemoglobin response with fewer infusions. Routine erythropoiesis-stimulating agent dose adjustment is expected when IV iron is added to a CKD anemia regimen 7.

Hepatic impairment

Hepatic impairment does not require dose adjustment of oral or IV iron per current product labeling. Iron storage in the liver should be monitored in patients with hepatic disease and repeated IV iron to avoid iron-overload-mediated hepatic injury 35.

Evidence quality

Iron (Compounded) Evidence Quality

The evidence base for iron repletion is one of the largest and most mature in clinical pharmacotherapy. Iron-deficiency anemia epidemiology is well characterized 2725. Oral iron pharmacokinetics, hepcidin biology, and dosing optimization have a strong recent mechanistic and clinical literature 302829. Indication-specific phase 3 trials support IV iron in CKD (DRIVE 7, FIND-CKD 8, REPAIR-IDA 9, FERWON-NEPHRO 12, PIVOTAL 10), in chronic and acute heart failure with iron deficiency (FAIR-HF 1, CONFIRM-HF 2, AFFIRM-AHF 3, IRONMAN 4, FERRIC-HF 5; oral iron negative in IRONOUT-HF 6), in inflammatory bowel disease (FERGIcor 11), and in iron-deficiency anemia broadly (FERWON-IDA 13, Hetzel et al. 14, Adkinson et al. 15). Pregnancy and HMB indications are framed by guideline consensus 1820 supported by epidemiologic mortality data 23. RLS is framed by IRLSSG consensus 19. Perioperative anemia is framed by international consensus 22 and PREVENTT 21. Comparative IV iron safety, particularly hypophosphatemia after FCM, is supported by direct randomized comparisons 161732.

Evidence specifically supporting compounded iron preparations is limited because the FDA-approved manufactured products dominate clinical use. The 503A role for iron is therefore narrow, custom oral concentrations and flavors for pediatric or dysphagic patients, alternate-day liquid pediatric formulations, and IM iron at non-commercial strengths in the rare patient who cannot use IV 35. RonanRx does not compound parenteral iron into multi-ingredient infusion bags.

Major studies

Major Iron (Compounded) Clinical Studies

StudyDesignParticipantsDurationFinding
FAIR-HF (Anker et al., NEJM 2009) Phase III randomized, double-blind, placebo-controlled trial of IV ferric carboxymaltose in chronic HFrEF with iron deficiency (ferritin <100 ng/mL, or 100, 299 with TSAT <20%) 459 24 weeks FCM significantly improved Patient Global Assessment and NYHA class vs placebo; benefit observed regardless of anemia status 1
CONFIRM-HF (Ponikowski et al., Eur Heart J 2015) Phase III randomized, double-blind, placebo-controlled, multicentre trial of IV ferric carboxymaltose in chronic HFrEF with iron deficiency 304 52 weeks Sustained improvement in 6-minute walk distance, NYHA functional class, and quality of life at 52 weeks; reduced first heart failure hospitalization 2
AFFIRM-AHF (Ponikowski et al., Lancet 2020) Multicentre randomized double-blind placebo-controlled trial of IV ferric carboxymaltose at discharge after acute heart failure with iron deficiency 1132 52 weeks Numerical reduction in composite of recurrent HF hospitalization and CV death; primary endpoint not statistically significant under prespecified COVID-19-adjusted analysis (RR 0.79, 95% CI 0.62, 1.01) 3
IRONMAN (Kalra et al., Lancet 2022) UK investigator-initiated, prospective, randomized, open-label, blinded-endpoint trial of IV ferric derisomaltose in chronic heart failure with iron deficiency 1137 Median 2.7 years Reduction in composite of HF hospitalizations and cardiovascular death in the COVID-19-adjusted analysis (RR 0.76, 95% CI 0.58, 1.00) 4
FERRIC-HF (Okonko et al., JACC 2008) Randomized observer-blind trial of IV iron sucrose vs no iron in iron-deficient symptomatic CHF, anemic and non-anemic strata 35 18 weeks Improved exercise tolerance, NYHA class, and symptom score with IV iron sucrose; preceded FAIR-HF 5
IRONOUT-HF (Lewis et al., JAMA 2017) Randomized double-blind placebo-controlled trial of oral iron polysaccharide complex vs placebo in HFrEF with iron deficiency 225 16 weeks Oral iron did not improve peak VO2, supports the IV route specifically in HFrEF 6
DRIVE (Coyne et al., J Am Soc Nephrol 2007) Multicentre randomized open-label trial of IV ferric gluconate vs no iron in anemic hemodialysis patients on erythropoietin with high ferritin (500, 1200 ng/mL) and low TSAT (≤25%) 134 6 weeks IV ferric gluconate produced meaningful hemoglobin response; challenged ferritin-based ceiling on IV iron in HD 7
FIND-CKD (Macdougall et al., NDT 2014) Randomized open-label trial of IV ferric carboxymaltose targeting two ferritin thresholds vs oral iron in non-dialysis CKD with IDA 626 56 weeks High-ferritin-target IV FCM superior to oral iron and to low-ferritin-target IV FCM on the composite Hb response endpoint 8
REPAIR-IDA (Onken et al., NDT 2014) Two identical phase 3 randomized open-label trials of IV ferric carboxymaltose vs iron sucrose in adults with IDA and non-dialysis CKD 2584 56 days FCM non-inferior to iron sucrose on mean Hb change; modestly higher transient blood pressure elevation post-FCM 9
PIVOTAL (Macdougall et al., NEJM 2019) UK multicentre randomized open-label trial of proactive high-dose vs reactive low-dose IV iron sucrose in incident hemodialysis patients 2141 Median 2.1 years Proactive high-dose IV iron non-inferior to reactive low-dose on composite of non-fatal MI, stroke, HF hospitalization, or death; reduced erythropoietin dose and transfusion requirement 10
FERGIcor (Evstatiev et al., Gastroenterology 2011) Multicentre randomized open-label trial of IV ferric carboxymaltose vs iron sucrose in adults with IBD and IDA 485 12 weeks FCM superior to iron sucrose on Hb response and required fewer infusions; established FCM as preferred IV iron in IBD 11
FERWON-IDA (Auerbach et al., Am J Hematol 2019) Multicentre randomized open-label trial of IV ferric derisomaltose vs iron sucrose in adults with IDA from various causes 1512 8 weeks FDI non-inferior to iron sucrose on Hb response and superior on time-to-response; supported FDA approval of Monoferric 13
FERWON-NEPHRO (Bhandari et al., NDT 2021) Multicentre randomized open-label trial of IV ferric derisomaltose vs iron sucrose in adults with non-dialysis CKD and IDA 1538 8 weeks FDI non-inferior to iron sucrose on Hb change with fewer infusions and comparable safety 12
Hetzel et al. (Am J Hematol 2014) Phase III multicentre randomized open-label trial of IV ferumoxytol vs iron sucrose in adults with IDA 605 5 weeks Ferumoxytol non-inferior to iron sucrose on Hb response; comparable safety profile 14
Adkinson et al. (Am J Hematol 2018) Multicentre randomized double-blind head-to-head trial of IV ferumoxytol vs ferric carboxymaltose in adults with IDA, comparative hypersensitivity safety 2014 Single-course follow-up Composite moderate-to-severe hypersensitivity reactions and moderate-to-severe hypotension broadly comparable between ferumoxytol and FCM; product-specific differences in AE subtypes 15
Wolf et al. (JAMA 2020) Two parallel phase 3 randomized open-label trials of IV ferric carboxymaltose vs ferric derisomaltose for hypophosphatemia as the primary outcome in adults with IDA 245 5 weeks Incident hypophosphatemia (<2.0 mg/dL) by day 14: 75% on FCM vs 8% on FDI in trial 1; similar magnitudes in trial 2; severe hypophosphatemia (<1.3 mg/dL) 11.3% on FCM vs 0% on FDI in trial 1 16
Schaefer et al. (JCEM 2022) Pooled analysis of randomized FCM trials for risk factors for persistent (>2-week) and severe hypophosphatemia — Pooled trial-level analysis Persistent hypophosphatemia common after FCM; risk factors include lower baseline phosphate, preserved renal function, and higher cumulative FCM dose; framework for routine post-FCM phosphate monitoring 17
PREVENTT (Richards et al., Lancet 2020) UK multicentre randomized double-blind placebo-controlled trial of preoperative IV ferric carboxymaltose 10, 42 days before major elective abdominal surgery in anaemic adults 487 8 weeks post-randomization plus surgical follow-up Co-primary endpoints (death or blood transfusion, number of transfusions) not met; pre-specified secondary analyses suggested fewer hospital readmissions and improved 8-week post-discharge Hb with IV iron 21
Stoffel et al. (Lancet Haematol 2017) Stable-isotope ⁵⁷Fe/⁵⁸Fe oral iron absorption study in iron-depleted young women 40 Single-course measurement Single morning doses on alternate days absorb more iron per dose and produce less hepcidin suppression of subsequent absorption than the same daily total split into twice-daily doses 28
Moretti et al. (Blood 2015) Stable-isotope oral iron absorption study in iron-depleted young women, mechanistic hepcidin biology 54 Single-course measurement Oral iron doses ≥60 mg significantly increase plasma hepcidin and reduce fractional iron absorption of subsequent doses within 24, 48 hours; mechanistic foundation for alternate-day dosing 30
Stoffel et al. (Haematologica 2020) Stable-isotope absorption study of alternate-day vs consecutive-day oral iron in iron-deficient anemic women 40 14-day course Cumulative iron absorption higher with alternate-day single-morning dosing than with consecutive-day dosing at matched daily dose; confirms hepcidin-mediated absorption ceiling 29
Tolkien et al. (PLoS One 2015) Systematic review and meta-analysis of GI adverse events with ferrous sulfate vs placebo and vs other oral iron preparations — Pooled trial-level analysis GI AE OR ≈2.32 vs placebo, ≈1.99 vs IV iron, and ≈1.45 vs other oral iron preparations; quantifies the GI-tolerability problem with daily ferrous sulfate 32
Avni et al. (Mayo Clin Proc 2015) Systematic review and meta-analysis of 103 RCTs of IV iron safety vs oral iron, IM iron, no iron, or placebo — Pooled trial-level analysis IV iron not associated with increased serious adverse events overall; severe hypersensitivity rare; established baseline IV iron safety frame 31
Kassebaum et al. (Blood 2014) Global Burden of Disease 2010 systematic analysis of anemia burden by cause, age, sex, year, region — 1990, 2010 GBD database Iron-deficiency anemia is the leading nutritional cause of years lived with disability worldwide; ~1.93 billion prevalent cases of anemia in 2010, with IDA the dominant subtype 27
Daru et al. (Lancet Glob Health 2018) Multilevel analysis of WHO Multicountry Survey on Maternal and Newborn Health linking severe maternal anaemia to mortality 312281 Cross-sectional with outcome ascertainment Severe maternal anaemia significantly associated with increased risk of maternal mortality (adjusted OR ~1.86); underlies urgency to correct severe antenatal IDA 23
Hutchinson et al. (Gut 2007) Controlled study of dietary non-heme iron absorption with and without omeprazole in hereditary haemochromatosis — — Proton pump inhibitor substantially reduced dietary non-heme iron absorption; mechanistic foundation for the well-documented PPI-iron interaction in repletion-failure cases 33
Auerbach et al. (Am J Hematol 2024), Expert consensus Multidisciplinary expert consensus guideline on intravenous iron uses, formulations, administration, and management of reactions — — Practical guidance on product selection, infusion protocols, hypersensitivity-reaction management, and post-FCM phosphate monitoring; framework adopted into current US practice 35
Auerbach et al. (JAMA 2025), State-of-the-art review Narrative review of diagnosis and management of iron deficiency and IDA in adults — — Synthesizes diagnostic ferritin thresholds (often higher than the historic <15 ng/mL given inflammation), alternate-day oral iron dosing, and modern IV iron product selection 36

Mechanism detail

Detailed Mechanism of Iron (Compounded)

Oral iron is absorbed predominantly in the duodenum and proximal jejunum. Non-heme iron (the form in supplements and most plant foods) is reduced from Fe³⁺ to Fe²⁺ at the apical enterocyte surface by duodenal cytochrome b and then transported across the apical membrane by DMT1. Heme iron is absorbed intact through HCP1. Within the enterocyte, iron is either stored in ferritin and lost when the enterocyte sloughs, or exported across the basolateral membrane by ferroportin and oxidized to Fe³⁺ by hephaestin for binding to transferrin in the circulation. Hepcidin, secreted by hepatocytes in response to iron, inflammation, and BMP6 signaling, binds ferroportin and triggers its internalization and degradation, which terminates further iron egress from the enterocyte and from macrophages.

A single oral iron dose increases serum hepcidin within 24 hours, blunting absorption of further iron given within that window. The Moretti, Stoffel, and follow-on studies in iron-deficient women established that single morning doses on alternate days absorb more total iron per administered dose than the same daily dose split twice daily, and that 60, 120 mg every other morning produces fractional absorption of 20, 35% on day 1 falling to 5, 10% on day 2 302829. This is the mechanistic rationale for alternate-day single-morning oral iron dosing, which also reduces GI symptom burden by halving the daily mucosal exposure 32. Proton pump inhibitors, H2 blockers, calcium, and polyphenol-rich tea all reduce non-heme iron absorption substantially 33.

Parenteral iron preparations are colloids in which an iron(III) oxyhydroxide core is stabilized by a carbohydrate shell. The shell determines several clinically important properties: the maximum single dose that can be safely administered (iron sucrose 200, 300 mg per dose vs FCM 750, 1000 mg per dose vs FDI up to 20 mg/kg single infusion vs ferumoxytol 510 mg per dose), the infusion duration required, the stability of free iron release in plasma (less stable formulations such as iron sucrose require multiple small doses; very stable formulations such as FCM and FDI permit total-dose infusion), and the immunogenicity (high-molecular-weight iron dextran historically caused most reported anaphylaxis; modern non-dextran preparations have rates 1, 2 orders of magnitude lower) 343531.

Iron from the parenteral colloid is delivered to reticuloendothelial macrophages, where it is sequestered in ferritin and then exported via ferroportin to transferrin in the plasma over hours to days. Free, non-transferrin-bound iron is potentially redox-active and can mediate oxidative stress at the infusion site or systemically, this is the basis of the 'Fishbane reaction' (transient flushing, chest tightness, back/joint pain) seen with too-rapid administration, and partly of FCM-associated hypophosphatemia. FCM specifically induces FGF23 cleavage products, causing renal phosphate wasting and frequently profound hypophosphatemia that may persist for weeks; this signal is markedly less pronounced with FDI and absent with iron sucrose, ferumoxytol, and iron dextran 1617.

Pharmacology

Iron (Compounded) Pharmacokinetics & Pharmacodynamics

Pharmacokinetics

Oral iron: only a small fraction (5, 20%) of an oral iron dose is absorbed in iron-replete adults; fractional absorption rises in iron deficiency. A single dose increases plasma hepcidin within 24 hours and reduces absorption of further doses given within that window; alternate-day single-morning dosing therefore absorbs more iron per administered dose than divided daily dosing 302829 34. Absorption is reduced by PPI, calcium, antacids, and tea polyphenols 33.

IV iron: each parenteral iron product has a distinctive PK profile determined by its carbohydrate shell. Iron sucrose is least stable, requiring multiple small doses; FCM and FDI are highly stable, supporting single-dose total-dose infusion of 750, 1000 mg; ferumoxytol supports 510 mg single doses. After infusion, iron is taken up by reticuloendothelial macrophages (liver, spleen, bone marrow), incorporated into ferritin storage, then exported to transferrin over hours to days for delivery to erythroid precursors. Serum iron and TSAT measurements within 1, 2 weeks of an IV iron dose reflect the colloid rather than the physiologically utilizable pool and should be interpreted with caution 3435.

Pharmacodynamics

Pharmacodynamic effect of iron repletion is reflected in: reticulocytosis within 5, 10 days; rise in hemoglobin of ≥1 g/dL by 2, 4 weeks of effective oral repletion (faster after a complete IV dose); normalization of ferritin and TSAT once stores are filled. Reversal of fatigue, exercise intolerance, and (in RLS) sensory-motor symptoms tracks repletion of the relevant iron pool, which for RLS appears to be brain-specific rather than systemic 19.

Negative pharmacodynamic effects: oral iron-induced hepcidin elevation transiently blunts intestinal iron absorption 30; FCM-induced FGF23 cleavage products drive renal phosphate wasting and hypophosphatemia for days to weeks 1617 19.

Comparative formulations

Comparing Iron (Compounded) Formulations

Oral iron preparations differ modestly in tolerability at matched elemental iron dose 35. Ferrous sulfate is the most widely studied and the cheapest; ferrous fumarate and ferrous gluconate are alternatives. Ferrous bisglycinate is often promoted as better tolerated; the evidence is mixed. Ferric maltol (Accrufer) is a newer oral preparation with a distinct GI tolerability profile but limited head-to-head data. Polysaccharide-iron complex products were negative on the primary VO2 endpoint of IRONOUT-HF in HFrEF 6.

IV iron preparations differ materially. Iron sucrose (Venofer) is the long-standing CKD-labeled option, dosed at 100, 300 mg per administration and typically requiring multiple visits 3538. Ferric carboxymaltose (Injectafer) and ferric derisomaltose (Monoferric) are total-dose-infusion-capable 3940. Ferumoxytol (Feraheme) is dosed in two 510 mg infusions 41. Low-molecular-weight iron dextran (INFeD) can deliver total-dose infusion but is now uncommon 42. The dominant comparative-safety axis between FCM and FDI is hypophosphatemia, which is far more frequent and severe with FCM 1617; the FCM-vs-ferumoxytol axis 15 is broadly balanced on composite hypersensitivity outcomes with distinct AE subtypes.

Storage

Iron (Compounded) Storage and Handling

Manufactured oral iron preparations are stored at controlled room temperature in light-resistant child-resistant containers. Compounded oral liquid iron is stored per the pharmacy's stability data and beyond-use date assignment under USP <795>; refrigerated storage may be required for some flavored preparations to maintain palatability and chemical stability 45.

Manufactured IV iron products are stored at controlled room temperature in their original carton; once diluted in normal saline they have a manufacturer-specified short in-use window 45. IV iron is not a cold-chain product. Each product has a specific permitted diluent and final-concentration window; deviation is a documented source of free-iron adverse reactions 393835.

RonanRx operations

Iron (Compounded) Compounding & Operations

503A compounding

Compounded iron preparations are prepared under 503A on patient-specific prescriptions in state-licensed compounding pharmacies 43. Nonsterile oral preparations (capsules, liquids) are governed by USP General Chapter <795>, with documented active ingredient sourcing, potency verification, and beyond-use date assignment per the pharmacy's quality-management system 45. The compounded role for iron is narrow because the FDA-approved manufactured oral and IV products are widely available and address most clinical needs.

Legitimate 503A iron-compounding scenarios at RonanRx include custom-strength oral liquid iron for pediatric or dysphagic adults (with alternate-day single-morning dosing per current absorption evidence 28) and custom-strength oral capsules where no manufactured product matches the prescribed regimen 43. RonanRx does not compound parenteral iron into multi-ingredient infusion bags and does not dispense 'iron infusions' as a routine wellness service: the manufactured IV iron products are the standard of care, and the physical-chemical incompatibilities of iron with amino-acid, B-vitamin, ascorbate, and thiol components of common 'cocktail' infusions are well documented 3539.

Pharmacist review

Each prescription for compounded iron undergoes pharmacist review prior to dispensing 44. The review confirms: a documented patient-specific clinical reason that the manufactured iron product is not appropriate (custom strength not available, excipient sensitivity, dysphagia, pediatric dose not matched by a commercial liquid); absence of iron-overload contraindications (HFE hemochromatosis with elevated ferritin, transfusional overload); a clinical workup for the underlying cause of iron deficiency (menstrual loss, GI loss, malabsorption, dietary inadequacy); and a prescribed regimen consistent with current evidence on alternate-day oral iron dosing 2829 where applicable.

RonanRx does not fill prescriptions that read as routine substitution of compounded for manufactured iron without documented clinical rationale, consistent with FDA guidance on compounded copies of commercially available drugs 44. RonanRx does not compound parenteral iron into multi-ingredient infusion bags under any circumstances 35.

Quality and traceability

Active pharmaceutical ingredients for compounded iron preparations are sourced from FDA-registered facilities with documented certificates of analysis. Each compounded batch is recorded with lot numbers traceable to API source, compounding date, beyond-use date, potency verification, and dispensing pharmacist of record. Finished product lot records are retained per state board of pharmacy retention requirements.

Cold chain

Oral iron, manufactured or compounded, is not a cold-chain product and is stored at controlled room temperature. Compounded flavored liquid iron preparations may require refrigeration to maintain palatability and chemical stability per the pharmacy's stability data 45. Manufactured IV iron products (iron sucrose, FCM, FDI, ferumoxytol, iron dextran) are also stored at controlled room temperature in original carton and are not cold-chain products 3938.

FAQ

Frequently Asked Questions About Iron (Compounded)

What is the best oral iron to take?

For most non-pregnant adults with iron-deficiency anemia, ferrous sulfate at 40, 100 mg elemental iron taken as a single morning dose every other day is well supported by recent absorption studies 282932. Other ferrous salts (fumarate, gluconate, bisglycinate) and oral ferric maltol are reasonable alternatives if ferrous sulfate is not tolerated. Take oral iron away from coffee, tea, calcium, antacids, and proton pump inhibitors 3033.

When is IV iron preferred over oral iron?

When oral iron has failed, is not tolerated, is contraindicated (active inflammatory bowel disease, post-bariatric surgery), or when rapid repletion is needed (late pregnancy with severe IDA, pre-operative anemia, dialysis CKD, decompensated heart failure with iron deficiency). The choice between IV iron products is driven by access, single-dose-infusion capability, and product-specific safety considerations such as the higher hypophosphatemia rate with ferric carboxymaltose 3516.

Are IV iron infusions dangerous?

Modern non-dextran IV iron preparations (iron sucrose, ferric carboxymaltose, ferric derisomaltose, ferumoxytol) have a serious-hypersensitivity-reaction rate of approximately 0.04, 0.1 per 100 administrations, much lower than the historic high-molecular-weight iron dextrans 3115. Mild infusion reactions (transient flushing, chest tightness, back/joint pain) occur with too-rapid administration and resolve with infusion-rate reduction. IV iron should be administered in a setting equipped to manage hypersensitivity reactions 3435.

Why does ferric carboxymaltose cause low phosphate?

FCM increases circulating intact FGF23 cleavage products, which drive renal phosphate wasting. In randomized comparison with ferric derisomaltose, FCM produced hypophosphatemia (<2.0 mg/dL) in 75% of patients by day 14 vs 8% on FDI 1617. The effect can be severe and prolonged, can cause weakness and bone pain, and, with repeated dosing, has been associated with osteomalacia and stress fractures. Routine pre- and post-FCM phosphate monitoring is recommended, and ferric derisomaltose is preferred when repeated IV iron is anticipated 35.

Does RonanRx compound 'iron drips' or IV iron cocktails?

No. RonanRx does not compound parenteral iron into multi-ingredient infusion bags and does not dispense IV iron as a routine wellness service. Iron is physically and chemically incompatible with many components of common 'cocktail' infusions, and the FDA-approved manufactured IV iron products (Venofer, Injectafer, Monoferric, Feraheme, INFeD) are the standard of care 353938.

What is the 503A role for compounded iron?

Custom-strength oral liquid iron for pediatric or dysphagic patients where no manufactured product matches the prescribed regimen (including alternate-day single-morning dosing schedules), excipient-free or specific-excipient oral preparations for patients with documented sensitivity, and (rarely) IM iron at non-commercial strengths 28. All are dispensed only on a patient-specific prescription with documented clinical rationale 4344.

Should I take iron if I have low ferritin but normal hemoglobin?

Iron deficiency without anemia can cause fatigue and (with low brain iron) restless legs syndrome 19. Current expert reviews support evaluating ferritin and considering iron repletion in non-anemic iron-deficient adults symptomatic of deficiency, but caution against routine IV iron for fatigue alone without documented deficiency and underlying cause workup 3536. Talk to your clinician about your ferritin number in context.

Who should not take iron?

Patients with iron overload, HFE hemochromatosis with elevated ferritin, transfusional overload, other primary iron-loading disorders, and patients with a history of serious hypersensitivity reaction to a specific IV iron product. Anemia not caused by iron deficiency is not an indication for iron therapy. Caution in active systemic infection, where IV iron is typically deferred until the infection is controlled 3538.

Clinician resource

Download the Iron (Compounded) Clinical Monograph (PDF)

The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.

Download information packet ↓

References

References

  1. [anker2009] Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Ponikowski P, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Anker SD; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. New England Journal of Medicine. 2009. PMID 19920054. (accessed 2026-05-11)
  2. [ponikowski2015] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.. European Heart Journal. 2015. PMID 25176939. (accessed 2026-05-11)
  3. [ponikowski2020] Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA; AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.. Lancet. 2020. PMID 33197395. (accessed 2026-05-11)
  4. [kalra2022] Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022. PMID 36347265. (accessed 2026-05-11)
  5. [okonko2008] Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.. Journal of the American College of Cardiology. 2008. PMID 18191732. (accessed 2026-05-11)
  6. [lewis2017] Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017. PMID 28510680. (accessed 2026-05-11)
  7. [coyne2007] Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Journal of the American Society of Nephrology. 2007. PMID 17267740. (accessed 2026-05-11)
  8. [macdougall2014] Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology Dialysis Transplantation. 2014. PMID 24891437. (accessed 2026-05-11)
  9. [onken2014] Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, Barish C, Bhaskar BS, Smith-Nguyen GN, Butcher A, Koch TA, Goodnough LT. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrology Dialysis Transplantation. 2014. PMID 23963731. (accessed 2026-05-11)
  10. [macdougall2019] Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.. New England Journal of Medicine. 2019. PMID 30365356. (accessed 2026-05-11)
  11. [evstatiev2011] Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011. PMID 21699794. (accessed 2026-05-11)
  12. [bhandari2021] Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrology Dialysis Transplantation. 2021. PMID 32049331. (accessed 2026-05-11)
  13. [auerbach2019_ferwon_ida] Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. American Journal of Hematology. 2019. PMID 31243803. (accessed 2026-05-11)
  14. [hetzel2014] Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology. 2014. PMID 24639149. (accessed 2026-05-11)
  15. [adkinson2018] Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, Chertow GM, Krop JS. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. American Journal of Hematology. 2018. PMID 29417614. (accessed 2026-05-11)
  16. [wolf2020] Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020. PMID 32016310. (accessed 2026-05-11)
  17. [schaefer2022] Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. Journal of Clinical Endocrinology and Metabolism. 2022. PMID 34850000. (accessed 2026-05-11)
  18. [pavord2020] Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. British Journal of Haematology. 2020. PMID 31578718. (accessed 2026-05-11)
  19. [allen2018_rls] Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelman JW; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.. Sleep Medicine. 2018. PMID 29425576. (accessed 2026-05-11)
  20. [mansour2021_hmb] Mansour D, Hofmann A, Gemzell-Danielsson K. A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding. Advances in Therapy. 2021. PMID 33247314. (accessed 2026-05-11)
  21. [richards2020] Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, Macdougall IC, Murphy G, Swinson R, Collier T, Van Dyck L, Browne J, Bradbury A, Dodd M, Evans R, Brookes C, Talboys R, Hodge R, Heyes J, Pegg E, Cresswell C, Belete E, Cooper J, Berry C, Lawrence A, Watkins P, Mathew A, Hill C, Ruder C, Gohil S, Goss J, Roe T, Andersen N, Wells S, Munk T, Atkinson C, Reilly A, Quinn A, Jhanji S, Reay M, Goring N, Bedingfield S, Bartholomew S, Owens A, Robbins A, Tabreham S, Iliescu V, Klein A; PREVENTT Trial Collaborators. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet. 2020. PMID 32896294. (accessed 2026-05-11)
  22. [munoz2017] Muñoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, Liumbruno GM, Lasocki S, Meybohm P, Rao Baikady R, Richards T, Shander A, So-Osman C, Spahn DR, Klein AA. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017. PMID 27996086. (accessed 2026-05-11)
  23. [daru2018] Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N, Tunçalp Ö, Torloni MR, Mittal S, Jayaratne K, Lumbiganon P, Togoobaatar G, Thangaratinam S, Khan KS. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. Lancet Global Health. 2018. PMID 29571592. (accessed 2026-05-11)
  24. [camaschella2015] Camaschella C. Iron-deficiency anemia. New England Journal of Medicine. 2015. PMID 25946282. (accessed 2026-05-11)
  25. [lopez2016] Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016. PMID 26314490. (accessed 2026-05-11)
  26. [pasricha2021] Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021. PMID 33285139. (accessed 2026-05-11)
  27. [kassebaum2014] Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, Regan M, Weatherall D, Chou DP, Eisele TP, Flaxman SR, Pullan RL, Brooker SJ, Murray CJ. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014. PMID 24297872. (accessed 2026-05-11)
  28. [stoffel2017] Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW, Moretti D, Zimmermann MB. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematology. 2017. PMID 29032957. (accessed 2026-05-11)
  29. [stoffel2020] Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020. PMID 31413088. (accessed 2026-05-11)
  30. [moretti2015] Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, Melse-Boonstra A, Brittenham G, Swinkels DW, Zimmermann MB. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015. PMID 26289639. (accessed 2026-05-11)
  31. [avni2015] Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clinic Proceedings. 2015. PMID 25572192. (accessed 2026-05-11)
  32. [tolkien2015] Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015. PMID 25700159. (accessed 2026-05-11)
  33. [hutchinson2007] Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007. PMID 17344278. (accessed 2026-05-11)
  34. [auerbach2017_history] Auerbach M, Macdougall IC. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodialysis International. 2017. PMID 28371203. (accessed 2026-05-11)
  35. [auerbach2024_consensus] Auerbach M, DeLoughery TG, Tirnauer JS. Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions. American Journal of Hematology. 2024. PMID 38282557. (accessed 2026-05-11)
  36. [auerbach2025_jama] Auerbach M, Adamson JW. Iron Deficiency in Adults: A Review. JAMA. 2025. PMID 40159291. (accessed 2026-05-11)
  37. [means2020] Means RT. Iron Deficiency and Iron Deficiency Anemia: Implications and Impact in Pregnancy, Fetal Development, and Early Childhood Parameters. Nutrients. 2020. PMID 32053933. (accessed 2026-05-11)
  38. [fda_label_venofer] U.S. Food and Drug Administration. Venofer (iron sucrose injection) — FDA Prescribing Information. FDA Drug Approval Package. 2020. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=venofer (accessed 2026-05-11)
  39. [fda_label_injectafer] U.S. Food and Drug Administration. Injectafer (ferric carboxymaltose injection) — FDA Prescribing Information. FDA Drug Approval Package. 2023. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=injectafer (accessed 2026-05-11)
  40. [fda_label_monoferric] U.S. Food and Drug Administration. Monoferric (ferric derisomaltose injection) — FDA Prescribing Information. FDA Drug Approval Package. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208171s000lbl.pdf (accessed 2026-05-11)
  41. [fda_label_feraheme] U.S. Food and Drug Administration. Feraheme (ferumoxytol injection) — FDA Prescribing Information. FDA Drug Approval Package. 2018. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=feraheme (accessed 2026-05-11)
  42. [fda_label_infed] U.S. Food and Drug Administration. INFeD (iron dextran injection USP) — FDA Prescribing Information. FDA Drug Approval Package. 2009. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=infed (accessed 2026-05-11)
  43. [fda503a] U.S. Food and Drug Administration. Compounding Laws and Policies — Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA Drug Compounding. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies (accessed 2026-05-11)
  44. [fda_essentially_a_copy] U.S. Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry. FDA Guidance for Industry. 2018. https://www.fda.gov/media/98973/download (accessed 2026-05-11)
  45. [usp_795] United States Pharmacopeia. USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations. USP Compounding Compendium. 2023. https://www.usp.org/compounding/general-chapter-795 (accessed 2026-05-11)

How to access

How to Access Iron (Compounded)

Compounded Iron (Compounded) is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.

For doctors

Offer this medication.

A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.

Offer this medication →

Patient with a doctor

Receive your prescription.

If your doctor has already prescribed Iron (Compounded), sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.

Sign up →

Patient without a doctor

Find a partner clinic.

RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Iron (Compounded).

Find a partner clinic →

Related